FDA Brief

Warning letters Devices

FDA warning letter to

Fischer Analysen Instrumente Gmbh

MediumIssued Feb 3, 2023Posted Feb 21, 2023Center for Devices and Radiological Health

FDA warns Fischer Analysen Instrumente over quality system and reporting failures for PyloPlus UBT analyzers.

What happened

FDA inspected the Leipzig, Germany facility Nov. 1-4, 2022 and found the PyloPlus UBT System 13/12CO2 breathing gas analyzer adulterated (not meeting required quality rules) and misbranded under medical device reporting rules. FDA said the company's Nov. 25, 2022 response was not adequate.

What FDA found

  1. Software validation documentation for PyloPlus software revision 1.49 was missing or inadequate, including plans, requirements, test approval, results, and validation of the QC lower-limit change.

    21 CFR 820.30(g)
  2. CAPA (corrective and preventive action) procedures did not adequately identify sources to analyze, statistical methods, root cause investigations, or effectiveness checks.

    21 CFR 820.100(a)
  3. Complaint procedures did not ensure timely and uniform handling, oral complaint documentation, MDR evaluation, investigation records, or replies to complainants.

    21 CFR 820.198
  4. Excel spreadsheets used for complaint and CAPA records were not validated, and changes or deletions were not tracked.

    21 CFR 820.70(i)
  5. No documentation was available for inspection, check, or maintenance of equipment used to assess pumps during production and repair.

    21 CFR 820.72(a)
  6. MDR (medical device reporting) procedures were incomplete: they lacked required definitions, timely event evaluation, report submission instructions, and recordkeeping.

    21 CFR 803.17

What FDA wants

FDA asks the firm to notify it in writing within 15 business days of receipt with specific steps taken, how it will prevent recurrence, documentation of corrections, and a timetable for actions that will take longer; non-English documents must be translated.

Who should pay attention

  • distributors and US agents of imported diagnostic devices
  • medical device makers using spreadsheets for quality records
  • quality teams responsible for complaint handling and MDR reporting

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Linemaster Switch Corporation

    Linemaster Switch Corporation, a Connecticut maker of foot pedals for medical lasers, was cited for quality system failures after an FDA inspection.

    High risk
  2. Laboratorios Jaloma S.A. de C.V.

    FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.

    High risk
  3. Hong Qiangxing Shenzhen Electronics Limited

    FDA warned Hong Qiangxing Shenzhen Electronics after an inspection found quality-system violations in TENS, muscle stimulator, and blood pressure monitor manufacturing.

    Medium
  4. Spectra Therapy, LLC

    FDA warns Spectra Therapy over LASERwrap infrared lamp device quality-system violations and unapproved disease-treatment claims.

    High risk